报价延迟最少15分钟:2025/01/21 08:56 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
-- 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.94/-0.61
|
|
企业价值
2.71B
|
| 资产负债 |
|
每股账面净值
3.62
|
| 现金流量 |
|
现金流量率
0.00
|
| 损益表 |
|
收益
747.72M
|
|
每股收益
11.75
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/01/21 08:56 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days. |